Statement of Changes in Beneficial Ownership (4)
November 06 2020 - 3:49PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
TANG KEVIN C |
2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc.
[
APVO
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
4747 EXECUTIVE DRIVE, SUITE 210 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/4/2020 |
(Street)
SAN DIEGO, CA 92121
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 11/4/2020 | | P | | 68296 | A | $10.63 (1) | 391621 | I (2) | By LP (2) |
Common Stock | 11/4/2020 | | P | | 88379 | A | $13.11 (3) | 480000 | I (2) | By LP (2) |
Common Stock | 11/4/2020 | | P | | 160000 | A | $13.83 (4) | 640000 | I (2) | By LP (2) |
Common Stock | 11/4/2020 | | P | | 99854 | A | $13.65 (5) | 739854 | I (2) | By LP (2) |
Common Stock | 11/4/2020 | | P | | 60146 | A | $16.33 (6) | 800000 | I (2) | By LP (2) |
Common Stock | 11/4/2020 | | P | | 160000 | A | $16.84 (7) | 960000 | I (2) | By LP (2) |
Common Stock | 11/5/2020 | | P | | 160000 | A | $15.31 (8) | 1120000 | I (2) | By LP (2) |
Common Stock | 11/5/2020 | | P | | 77133 | A | $14.22 (9) | 1197133 | I (2) | By LP (2) |
Common Stock | 11/5/2020 | | P | | 71241 | A | $15.32 (10) | 1268374 | I (2) | By LP (2) |
Common Stock | 11/5/2020 | | P | | 171626 | A | $23.79 (11) | 1440000 | I (2) | By LP (2) |
Common Stock | 11/5/2020 | | P | | 137241 | A | $20.78 (12) | 1577241 | I (2) | By LP (2) |
Common Stock | 11/5/2020 | | P | | 8482 | A | $20.94 (13) | 1585723 | I (2) | By LP (2) |
Common Stock | 11/6/2020 | | P | | 34044 | A | $20.63 (14) | 1619767 | I (2) | By LP (2) |
Common Stock | 11/6/2020 | | P | | 29682 | A | $22.33 (15) | 1649449 | I (2) | By LP (2) |
Common Stock | 11/6/2020 | | P | | 107901 | A | $23.48 (16) | 1757350 | I (2) | By LP (2) |
Common Stock | 11/6/2020 | | P | | 2650 | A | $23.87 (17) | 1760000 | I (2) | By LP (2) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $10.11 to $11.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 17 herein. |
(2) | The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. |
(3) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $12.88 to $13.44. |
(4) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.33 to $14.00. |
(5) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.18 to $14.00. |
(6) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $16.18 to $16.45. |
(7) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $16.33 to $17.00. |
(8) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $14.74 to $15.50. |
(9) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.98 to $14.93. |
(10) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $14.98 to $15.50. |
(11) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $23.09 to $24.00. |
(12) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $20.18 to $21.00. |
(13) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $20.86 to $21.00. |
(14) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $20.10 to $21.00. |
(15) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $21.85 to $22.84. |
(16) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $22.85 to $23.84. |
(17) | The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $23.85 to $23.87. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
TANG KEVIN C 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO, CA 92121 |
| X |
|
|
TANG CAPITAL MANAGEMENT LLC 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO, CA 92121 |
| X |
|
|
TANG CAPITAL PARTNERS LP 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO, CA 92121 |
| X |
|
|
Signatures
|
/s/ Kevin Tang | | 11/6/2020 |
**Signature of Reporting Person | Date |
/s/ Kevin Tang, Managing Member | | 11/6/2020 |
**Signature of Reporting Person | Date |
/s/ Kevin Tang, Managing Member of Tang Capital Management, LLC, General Partner | | 11/6/2020 |
**Signature of Reporting Person | Date |
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Jul 2023 to Jul 2024